Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Human Adipose Tissue-Derived Mesenchymal Stem Cells in Parkinson's Disease: Inhibition of T Helper 17 Cell Differentiation and Regulation of Immune Balance Towards a Regulatory T Cell Phenotype.

Bi Y., Lin X., Liang H., Yang D., Zhang X., Ke J.

Prospective Study on Neuroinflammation, Immune Modulation, published in Clin Interv Aging (2020) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Clin Interv Aging (2020)
Country
New Zealand
Reported sample size
—
Source database
PubMed
PMID
32884248
PMCID
PMC7434526
DOI
10.2147/CIA.S259762
Citations
34

Abstract (original English)

Background Parkinson's disease (PD) is a neurodegenerative disorder displaying a typical neuroinflammation pathology that may result from an imbalance between regulatory T cells (Treg) and T helper 17 (Th17) cells. Human adipose tissue-derived mesenchymal stem cells (Ad-MSCs) exert immunomodulatory effects by inhibiting effector T cell responses and have been used to treat diverse immune disorders. We aimed to investigate the modulating effect of human Ad-MSCs on peripheral blood mononuclear cells (PBMCs) of patients with PD, focusing on differentiation into Th17 and Treg cells. Methods We isolated human peripheral blood CD4 + T cells and co-cultured them with Ad-MSCs at a ratio of 4:1 under either Th17 or Treg cell polarizing conditions for 4 days to detect the proportions of IL-17-producing CD4 + T (Th17) and CD4 + CD25 + Foxp3 + regulatory T (Treg) cells by flow cytometry. We also determined the mRNA expression levels of the retinoid-related orphan nuclear receptor (RORγt) transcription factor and those of interleukin-6 receptor (IL-6R), interleukin-23 receptor (IL-23R), leukemia inhibitory factor (LIF), and LIF receptor (LIFR) by quantitative reverse transcription PCR. We detected levels of cytokines in the supernatant (including LIF, IL-6, IL-23, IL-10, and TGF-β) using ELISA. Results Our results showed that Ad-MSCs specifically inhibited the differentiation of PBMCs of pa

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Cell DifferentiationCells, CulturedHumansInterleukin-10Interleukin-2 Receptor alpha SubunitLeukemia Inhibitory FactorLeukocytes, MononuclearMesenchymal Stem CellsNuclear Receptor Subfamily 1, Group F, Member 3Parkinson Disease

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research